Comparison of the Effects of Antidepressants with Different Mechanisms of Action on Efficacy, Cognitive Functions and Side Effects. / Farkli Etki Mekanizmasina Sahip Antidepresanlarin Etkinlik, Bilissel Islevler ve Yan Etki Açisindan Karsilastirilmasi.

OBJECTIVE: The aim of this study was to compare the effects of the agomelatine and selective serotonin reuptake inhibitors (SSRIs) on symptoms of depression, cognitive functions, impulsiveness, suicidal tendency, sleep pattern and side effects. METHOD: This study enrolled patients with depression started on SSRIs (n=30) or agomelatine (n=30) on an outpatient basis. All patients were evaluated with SCID-I and the Sociodemographic Questionnaire on the first day of the treatment. In order to assess the side effects of the treatments, the patients were assessed at the first and the fourth weeks with Hamilton Depression Scale (HAM-D), the Suicide Probability Scale (SPS), the UPSS Impulsive Behaviour Scale, the Epworth Sleepiness Scale (ESS), the UKU Side Effect Rating Scale, and the Stroop Test and the Trail Making Test for cognitive functions. . RESULTS: Patients on SSRIs showed better treatment response and remission rates at the end of the first month. Improvement in cognitive functions correlated with the decrease in depressive symptoms, but no difference was observed between the groups with respect to the improvement of the cognitive functions. SSRIs caused more autonomic and sexual side effects compared to agomelatine. Differences were not observed between the effects of the two medications on impulsivity, sleep pattern and suicidal tendency. CONCLUSION: In conclusion, treatment with SSRIs was significantly more associated with improvement in the clinical symptoms. Sexual side effects were more prevalent with SSRIs, but the effect on cognitive functions did not differ from agomelatine Despite the distinct, promising mechanism of action, agomelatine was not as effective as the SSRIs for the treatment of depression.

Optical coherence tomography neurodegenerative findings in patients with bipolar disorder.

INTRODUCTION: Neuroimaging studies of patients with bipolar disorder (BD) have recently revealed neurodegenerative changes in the central nervous system. Optical coherence tomography (OCT) imaging of the retina, as an extension of brain, may be a biomarker in understanding the neurobiology of the disease. To assess OCT as a tool to detect neurodegeneration in BD we compared the retinal changes between patients with BD and healthy individuals. METHODS: We performed complete ophthalmological examinations and took OCT images for 70 eyes of 70 patients with BD, and for age and sex-matched individual controls. We compared retinal nerve fiber layers (RNFLs) and total retinal (TR) thickness in the peripapillary areas; and ganglion cell complexes (GCCs) and TR thickness in the maculas between the groups. RESULTS: The mean age of the patients was 40.41 ± 13.22 years and that of the controls 40.20 ± 13.03 years. The men/women ratios were 37/33 in both groups. BD was significantly associated with a decrease in the average peripapillary RNFL, with the average peripapillary TR, and with the average GCC thickness (P = .033, P = .008, and P = .009, respectively). The peripapillary RNFL and TR thinnings were prominent in the superior (P = .039, P = .033, respectively) and inferior quadrants (P = .031, P = .018, respectively). The BD effects on GCC thinning was prominent in the superior half (P = .001) and in the nasal sectors (except in the inner superonasal sector; all P < .05). BD was associated with a decrease in macular TR thickness only at the inner superior sector (P = .014). Disease duration was inversely correlated with the peripapillary RNFL, TR, and macular GCC thicknesses (P < .05). DISCUSSION: Our findings support the neurodegeneration hypothesis in the etiopathogenesis of BD. OCT, a non-invasive neuro-imaging method, may be useful for BD diagnosis and follow-ups.

Olfactory bulbus volume and olfactory sulcus depth in psychotic patients and patients with anxiety disorder/depression.

OBJECTIVES: In the present study, we investigated olfactory bulb (OB) volume and olfactory sulcus (OS) depth of the psychotic patients (predominantly schizophrenia) and patients with anxiety disorder/depression. METHODS: This study was conducted retrospectively. Group 1 consisted of 30 psychotic patients (predominantly schizophrenia) (19 males and 11 females). Group 2 consisted of 37 patients with anxiety disorder/depression (10 males, 27 females). Group 3 consisted of 30 non-psychotic and non-anxiety disorder/depression subjects (9 males and 21 females). OB volume and OS depth measurements were performed on Cranial MRI. RESULTS: OB volume (right and left) of the psychotic; and anxiety disorder/depression groups were significantly lower than those of the control group (padjusted < 0.0175). OS depth (Left) value of anxiety disorder/depression group was significantly lower than those of the control group (padjusted < 0.0175). In psychotic and anxiety disorder/depression groups, left OS depth values were significantly lower than those of the right side (p < 0.05). In each of the males and females of the anxiety disorder/depression group, left OS depth values were significantly lower than those of the right side (p < 0.05). In psychotic group, OS depth (left) values get lower in older patients (p < 0.05). CONCLUSION: Decreased OB volume in the psychotic patients and decreased OB volume and OS depth in anxiety disorder/depression patients were detected. Lower OB volume and OS depth are related to the olfactory loss/or olfactory impairment. Physicians should be aware of the olfactory deficits in psychotic patients (mainly schizophrenia) and patients with anxiety disorder/depression. When reduced OB volume is detected on MRI, psychosis, schizophrenia or depression should also be kept in mind and the patients should be evaluated in detail for these diseases.

The effect of temperament on the treatment adherence of bipolar disorder type I.

BACKGROUND AND AIMS: Treatment adherence is one of the most important factors that may determine treatment response in patients with bipolar disorders (BD). Many factors have been described to be associated with treatment adherence in BD. Temperament that can influence the course of BD will have an impact on treatment adherence. The aim of this study is to investigate temperament effect on treatment adherence in euthymic patients with BD-I. METHODS: Eighty patients with BD-I participated in the study. A psychiatrist used the Structured Clinical Interview for DSM-IV Axis-I Disorders to determine the diagnosis and co-morbidities. Hamilton Depression and Young Mania Rating Scale were used to detect the remission. We used the Temperament Evaluation of Memphis, Pisa, Paris, San Diego Autoquestionnaire and the 4-item Morisky Medication Adherence Scale to evaluate temperament and treatment adherence, respectively. The study group was divided into two groups as "treatment adherent" and "treatment non-adherent". RESULTS: The cyclothymic and anxious temperament scores of the treatment non-adherent patients with BD-I were significantly higher than those of the treatment adherent group (p < 0.001, p = 0.006, respectively). Multiple linear regression analysis determined that cyclothymic temperament predicted treatment non-adherence (p = 0.009). CONCLUSION: It should be kept in mind that BD-I patients with cyclothymic temperament may be treatment non-adherent and future studies should explore whether temperament characteristics deteriorate BD-I course by disrupting treatment adherence.

Effects of comorbid anxiety disorders on the course of bipolar disorder-I.

BACKGROUND AND AIMS: Although comorbid anxiety disorders (AD) are quite frequent in bipolar disorders (BD), data on how this comorbidity affects BD are limited. In the present study, we aimed to investigate the frequency of comorbid AD in Turkish patients with bipolar disorder-I (BD-I) and the effects of comorbid AD on the course of BD-I. METHODS: 114 patients with BD-I were included in the study. All patients were diagnosed by a psychiatrist. The patients were divided into two groups as BD-I patients with lifetime comorbid AD (BDI-CAD) or those without comorbid AD (BDI). RESULTS: 37 (32.46%) patients had one or more comorbid lifetime AD. The numbers of admissions to the outpatient clinic within calendar year 2013 (P = 0.014), the number of lifetime mood episodes (P = 0.019) and the duration of BD (P = 0.007) were higher in the BDI-CAD group compared with the BDI group. There was a strong relationship between the duration of the disorder and the number of episodes (r = 0.583, P < 0.001). Partial correlation analyses showed that the number of admission to the outpatient clinic correlated significantly with the frequency of episodes (P = 0.007, r = 0.282). CONCLUSION: We found that the patients with BDI-CAD use the healthcare system more frequently than the BDI patients. This suggests that AD comorbidity may have a negative influence on the course of BD-I and it is a factor that should be considered in the clinical follow-up.